Abstract
A new high-performance thin-layer chromatographic (HPTLC) method has been established for determination of mycophenolate mofetil in human plasma. Mycophenolate mofetil is used as an important immunosuppressive agent. Chromatographic separation was performed on aluminium plates coated with silica gel 60F254; the mobile phase was a combination of triethylamine buffer (pH 5.3) and acetonitrile in the ratio of 20:80 (v/v) respectively. Densitometric analysis of mycophenolate mofetil was performed at 250 nm. The method was rapid (single-step extraction with acetonitrile), sensitive (limit of quantification 15.4 ng per zone), precise (CV ≤ 3.71 %), accurate (drug recovery 95.08-100.6%), and linear over the range 100-1200 ng per zone. Recovery of mycophenolate mofetil from plasma samples was 95.8 ± 4.5%. The half-life of mycophenolate mofetil in plasma was 20.4 h at 4°C and 17.8 h at 20°C. Mycophenolate mofetil is stable in human plasma for at least two months at -20°C and can tolerate two freeze-thaw cycles with losses < 10%. The method was successfully used to determine therapeutic levels of mycophenolate mofetil.
Keywords: Mycophenolate mofetil, High-performance thin-layer chromatography, Human plasma, Densitometric analysis, Limit of quantification, Liquid chromatographic mass spectrometry, Specificity, Freeze-Thaw Stability, Precision, Accuracy
Current Analytical Chemistry
Title: Validated, Stability Indicating HPTLC Method for the Determination of Mycophenolate Mofetil in Human Plasma
Volume: 7 Issue: 3
Author(s): Suraj P. Verma, Sadaf J. Gilani, Indu Bala, D. P. Maurya, Ozair Alam, Nadeem Siddique and Suroor A. Khan
Affiliation:
Keywords: Mycophenolate mofetil, High-performance thin-layer chromatography, Human plasma, Densitometric analysis, Limit of quantification, Liquid chromatographic mass spectrometry, Specificity, Freeze-Thaw Stability, Precision, Accuracy
Abstract: A new high-performance thin-layer chromatographic (HPTLC) method has been established for determination of mycophenolate mofetil in human plasma. Mycophenolate mofetil is used as an important immunosuppressive agent. Chromatographic separation was performed on aluminium plates coated with silica gel 60F254; the mobile phase was a combination of triethylamine buffer (pH 5.3) and acetonitrile in the ratio of 20:80 (v/v) respectively. Densitometric analysis of mycophenolate mofetil was performed at 250 nm. The method was rapid (single-step extraction with acetonitrile), sensitive (limit of quantification 15.4 ng per zone), precise (CV ≤ 3.71 %), accurate (drug recovery 95.08-100.6%), and linear over the range 100-1200 ng per zone. Recovery of mycophenolate mofetil from plasma samples was 95.8 ± 4.5%. The half-life of mycophenolate mofetil in plasma was 20.4 h at 4°C and 17.8 h at 20°C. Mycophenolate mofetil is stable in human plasma for at least two months at -20°C and can tolerate two freeze-thaw cycles with losses < 10%. The method was successfully used to determine therapeutic levels of mycophenolate mofetil.
Export Options
About this article
Cite this article as:
P. Verma Suraj, J. Gilani Sadaf, Bala Indu, P. Maurya D., Alam Ozair, Siddique Nadeem and A. Khan Suroor, Validated, Stability Indicating HPTLC Method for the Determination of Mycophenolate Mofetil in Human Plasma, Current Analytical Chemistry 2011; 7 (3) . https://dx.doi.org/10.2174/1573411011107030216
DOI https://dx.doi.org/10.2174/1573411011107030216 |
Print ISSN 1573-4110 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6727 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Generation of Pharmacophore and Atom Based 3D-QSAR Model of Novel Isoquinolin-1-one and Quinazolin-4-one-type Inhibitors of TNFα
Medicinal Chemistry Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Pharmacophoric Modeling and Atom-Based 3D-QSAR of Novel 1-Aryl-3-(1-acylpiperidin-4-yl) Urea as Human Soluble Epoxide Hydrolase Inhibitors (sEHIs)
Medicinal Chemistry Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review
Recent Patents on Inflammation & Allergy Drug Discovery The GH/IGF-1 Axis and Heart Failure
Current Cardiology Reviews Partial QSAR Analysis of Some Selected Natural Inhibitors of FAAH Suggests a Working Hypothesis for the Development of Endocannabinoid- Based Drugs
Current Drug Targets - CNS & Neurological Disorders Lipid Raft Alterations in Aged-Associated Neuropathologies
Current Alzheimer Research Chondroitin Sulfate and Sulfur Containing Chondroprotective Agents: Is there a Basis for their Pharmacological Action?
Current Rheumatology Reviews Endoplasmic Reticulum and Mitochondria: Independent Roles and Crosstalk in Fatty Liver Diseases and Hepatic Inflammation
Current Pharmaceutical Design The Chemistry of Epoxy Alcohols
Current Organic Chemistry Editorial [Hot Topic: Bacterial Vectors for Gene & Cell Therapy (Guest Editors: Mark Tangney & Cormac G.M. Gahan)]
Current Gene Therapy Cardiovascular Drugs and Bone
Current Drug Safety Glioblastoma: Prognostic Factors and Predictive Response to Radio and Chemotherapy
Current Medicinal Chemistry Autonomic Dysfunction and Depression: A Biomarker of MDD Across the Life Span
Current Psychiatry Reviews Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Therapeutic Targeting of Type 2 Inflammation for the Treatment of Severe Asthma
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) The Adipocyte as a Novel TSH Target
Mini-Reviews in Medicinal Chemistry Current Management of Neonatal Soft-tissue Sarcomas and Benign Tumors with Local Aggressiveness
Current Pediatric Reviews Advances in Lipid-Based Subunit Vaccine Formulations
Current Immunology Reviews (Discontinued) Anti-Cancer, Pharmacokinetic and Biodistribution Studies of Cremophor EL Free Alternative Paclitaxel Formulation
Current Drug Safety